Lexaria Bioscience Corp (LEXX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 08/31
| 05-2023 | 02-2023 | 11-2022 | 08-2022 | 05-2022 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -5,464 | -3,080 | -1,769 | -7,384 | -5,871 |
| Depreciation Amortization | 75 | 50 | 25 | 103 | 78 |
| Accounts receivable | 30 | 65 | -85 | -138 | -91 |
| Other Working Capital | 858 | 378 | 342 | -352 | 113 |
| Other Operating Activity | 242 | 114 | 242 | 2,891 | 2,067 |
| Operating Cash Flow | $-4,260 | $-2,474 | $-1,245 | $-4,879 | $-3,703 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -34 | -34 | -21 | -49 | -49 |
| Purchase Sale Intangibles | -67 | -34 | -14 | -131 | -81 |
| Other Investing Activity | -68 | -34 | -14 | -131 | -81 |
| Investing Cash Flow | $-101 | $-68 | $-35 | $-181 | $-131 |
| Cash Flows From Financing Activities | |||||
| Debt Repayment | N/A | N/A | N/A | -45 | -33 |
| Common Stock Issued | 1,711 | 0 | N/A | N/A | 0 |
| Financing Cash Flow | $1,711 | $N/A | $N/A | $-45 | $-33 |
| Beginning Cash Position | 5,813 | 5,813 | 5,813 | 10,918 | 10,918 |
| End Cash Position | 3,164 | 3,272 | 4,533 | 5,813 | 7,051 |
| Net Cash Flow | $-2,649 | $-2,541 | $-1,280 | $-5,105 | $-3,867 |
| Free Cash Flow | |||||
| Operating Cash Flow | -4,260 | -2,474 | -1,245 | -4,879 | -3,703 |
| Capital Expenditure | -34 | -34 | -21 | -49 | -49 |
| Free Cash Flow | -4,293 | -2,507 | -1,266 | -4,929 | -3,752 |